Article
Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities.
Haematologica - 1 Jul 2011
Möllgård Lars, Saft Leonie, Treppendahl Marianne Bach, Dybedal Ingunn, Nørgaard Jan Maxwell, Astermark Jan, Ejerblad Elisabeth, Garelius Hege, Dufva Inge Høgh, Jansson Monika, Jädersten Martin, Kjeldsen Lars, Linder Olle, Nilsson Lars, Vestergaard Hanne, Porwit Anna, Grønbæk Kirsten, Hellström-Lindberg Eva, Lindberg Eva Hellström
Abstract excerpt
BACKGROUND: Patients with chromosome 5 abnormalities and high-risk myelodysplastic syndromes or acute myeloid leukemia have a poor outcome. We hypothesized that increasing doses of lenalidomide may benefit this group of patients by inhibiting the tumor clone, as assessed by fluorescence in situ hybridization for del(5q31). DESIGN AND METHODS: Twenty-eight patients at diagnosis or with relapsed disease and not...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.